FDA FORM 483 • GMP INSPECTION ANALYSIS
FDA Form 483 – Strides Pharma Science Limited | 2026 Inspection Observations
Practical GMP, Microbiology, Laboratory Controls, Data Integrity,
Equipment Cleaning and Computerized-System Lessons from FDA Inspectional Observations
🏢 Firm
Strides Pharma Science Limited
📍 Location
Bangalore, Karnataka, India
📅 FDA Inspection
May 12–20, 2026
📄 Document
FDA Form 483 – Inspectional Observations
⚠️ Educational Purpose Only
This page presents and explains FDA Form 483 inspectional observations
for educational, professional-development and GMP-awareness purposes.
The purpose is to help pharmaceutical professionals understand potential
quality-system weaknesses, inspection expectations and opportunities to
strengthen their own systems.
This article is not intended to criticize, defame, discredit or negatively
characterize Strides Pharma Science Limited, its management, employees,
or any individual associated with the inspection.
🔎 What Can Pharmaceutical Companies Learn From This FDA 483?
The FDA Form 483 provided for this article contains observations covering
important pharmaceutical quality-system areas. The document includes
five numbered observations, with several sub-points and
examples.
01
Microbiological Identification & Laboratory Controls
02
Electronic Records & Audit Trail Retention
03
Equipment Cleaning & Maintenance
04
Computerized Manufacturing Systems
05
Component Testing & USP Requirements
OBSERVATION 1
Microbiological Identification and Laboratory Control Systems
FDA Observation — Key Concern
The FDA stated that laboratory controls should include scientifically sound
and appropriate specifications, standards, sampling plans and test procedures
to assure that components, containers, closures, in-process materials,
labeling and drug products conform to appropriate standards of identity,
strength, quality and purity.
Microbiological Identification Method
The observation states that the microbiological identification method used
for confirmatory identification of specified microorganisms was not
validated or verified for its intended use.
The FDA also described concerns involving the use of a microbial
identification system for microorganisms recovered from finished drug
products, raw materials and environmental monitoring samples.
A. Testing Procedure and Sampling
The observation describes a testing procedure requiring testing of
specified samples and subsequent confirmatory identification using a
microbial identification system. The FDA questioned whether the
confirmatory identification system had been appropriately validated or
verified for its intended purpose.
B. Identification of Specified Organisms
The observation also discusses the firm's PQ documentation and the absence
of specified organism identification capability from the applicable
qualification documentation.
C. Method Suitability and Performance Qualification
The FDA described concerns regarding the firm's microbial identification
system, including qualification and the ability of the system to identify
specified microorganisms.
D. TAMC / Microbial Enumeration Result Handling
The observation discusses results for Total Aerobic Microbial Count (TAMC)
and the treatment of count results at or above the applicable reporting
range, including the use of the term TNTC.
E. Chromatography Data Processing Controls
The FDA also identified computerized-system access associated with
chromatography data processing. The observation describes a user having
permission to modify processing methods and discusses simultaneous viewing
and editing of regulated numerical results and chromatographic parameters.
💡 Pharmaceutical Microbiology Learning
Microbial identification systems should be appropriately qualified and
verified for their intended application. The organization should be able
to demonstrate method suitability, appropriate organism identification
capability, controlled data processing and scientifically justified
interpretation of microbiological results.
OBSERVATION 2
Electronic Records and Audit Trail Retention
FDA Observation — Records Retention
The FDA stated that records of production associated with a batch of drug
product were not maintained for at least one year after the expiration date.
Electronic Audit-Trail Data
The observation describes failure to establish procedures for review of
audit-trail data and failure to ensure that audit trails were reviewed as
part of investigations of manufacturing anomalies.
The FDA further described electronic audit-trail data being permanently
deleted after one year, including information associated with manufacturing
equipment.
Audit Trail Review
The observation states that audit-trail review for specified equipment was
performed by viewing data through the Human Machine Interface (HMI), without
generating or otherwise documenting the evidence of the review.
The FDA also noted uncertainty regarding what information the audit trail
contained at the time of review and described audit-trail information
being permanently deleted from the system after one year.
Review Frequency and Investigation of Anomalies
The observation describes a procedure that did not define a limit on the
number of times equipment parameters could be changed during processing,
nor did it establish a threshold for when such parameter changes should
be considered an anomaly requiring investigation.
💡 Data Integrity Learning
Audit trails should remain available for the required retention period,
be appropriately reviewed, and provide meaningful evidence of relevant
electronic activities. Procedures should define how audit-trail events
are assessed and when unusual activity requires investigation.
OBSERVATION 3
Equipment Cleaning and Maintenance Controls
The FDA stated that equipment and utensils were not cleaned and maintained
at appropriate intervals to prevent contamination or carryover that could
alter the safety, identity, strength, quality or purity of drug products.
Cleaning Observation
The inspection document describes observations involving equipment
condition, residues and cleaning activities within manufacturing areas.
The FDA referenced cleaning procedures and documentation associated with
serial and non-serial equipment and identified concerns regarding the
adequacy of cleaning practices and verification.
Carryover and Previous Product Residues
The observation describes equipment where residues associated with
previous product manufacture were identified and discusses the potential
for carryover if equipment is not adequately cleaned and maintained.
Manufacturing Area Cleaning
Additional examples describe observations during inspection of
manufacturing areas and equipment, including concerns involving residues
and cleaning activities following manufacturing operations.
Cleaning Verification
The FDA referenced cleaning documentation and verification activities
associated with equipment used for manufacturing.
💡 GMP Cleaning Learning
Cleaning programs should be designed around product risk, equipment
design, previous-product characteristics, cleaning procedures, acceptance
criteria, verification and documented evidence. Visible residues should
trigger appropriate quality-system assessment rather than being treated
as an isolated housekeeping issue.
OBSERVATION 4
Computerized Manufacturing Systems, Access Controls and Recipe Management
FDA Observation — Computerized Equipment
The FDA stated that appropriate controls were not exercised over
computerized manufacturing equipment to ensure that only authorized
personnel could create and modify recipes, obsolete or unauthorized
recipes were not used, and adequate audit trails were maintained.
A. Obsolete and Unauthorized Recipes
The observation describes obsolete and unauthorized recipes existing
simultaneously with functional and non-functional recipes, with concerns
that users could potentially select inappropriate recipes during
commercial manufacturing.
B. Recipe Selection and Access Controls
The FDA described equipment containing numerous obsolete recipes for the
same product code, with limitations in preventing selection of obsolete
recipes.
C. User Access and Privilege Management
The observation states that user access and privilege management controls
were inadequate, including concerns involving Quality Assurance and
production personnel access to computerized systems and recipe
creation/modification capabilities.
D. Documentation and Verification
The FDA also identified concerns regarding inadequate documentation and
verification for computer-based manufacturing records, including the
ability to verify which recipe was actually selected during manufacturing.
E. Recipe Lifecycle Management
The observation further describes the absence of adequate procedures for
recipe lifecycle management, including controls for recipe creation,
modification, approval, implementation and obsolescence.
💡 Data Integrity & GMP Learning
Computerized manufacturing systems require controlled user privileges,
approved recipe management, effective change control, appropriate
audit-trail functionality and controls that prevent obsolete or
unauthorized instructions from being inadvertently selected.
OBSERVATION 5
Component Testing for Conformity With Written Specifications
FDA Observation — Component Testing
The FDA stated that each component was not tested for conformity with
all written specifications for purity, strength and quality.
Testing Before Use
The observation describes failure to perform specified testing on each
shipment or applicable container requirements before the component was
used in manufacturing.
USP / Compendial Testing
The FDA identified examples where applicable USP testing had not been
performed on specified lots and described gaps between the effective date
of the applicable requirement and implementation of the corresponding
testing procedure.
Released Finished Product Batches
The observation includes examples of finished drug-product batches
manufactured and distributed to the U.S. market where the specified
testing had not been performed.
Why This Matters
Component testing is an important part of the overall pharmaceutical
quality-control system. Testing requirements should be appropriately
incorporated into specifications, procedures, laboratory methods,
material-control systems and batch-release processes.
💡 Industry Learning
When a new or revised compendial requirement becomes applicable,
organizations should ensure that the requirement is assessed,
incorporated into the appropriate quality documents and implemented
before affected materials or products proceed through the applicable
quality process.
🔬 What Are the Major GMP Themes?
🧫 Microbiology
Identification systems and microbiological testing should be fit for
their intended use.
💻 Data Integrity
Electronic records and audit trails need controlled retention and review.
🧼 Cleaning
Cleaning and maintenance must effectively control contamination and carryover.
🔐 Access Control
System privileges should match responsibilities and prevent unauthorized actions.
📋 Recipe Management
Approved, current recipes should be distinguishable from obsolete versions.
🧪 Laboratory Controls
Testing requirements should be scientifically sound and appropriately implemented.
🧭 Root Cause Investigation — Questions for Other Pharmaceutical Companies
The most useful lesson from an FDA observation is to determine whether
a finding represents an isolated event or a broader quality-system weakness.
01 — Procedure
Is the SOP technically correct, current and sufficiently detailed?
02 — Implementation
Is the approved procedure actually followed in routine operations?
03 — Training
Do personnel understand the requirements and system limitations?
04 — System Configuration
Are computerized systems configured according to GMP requirements?
05 — Quality Oversight
Is QA oversight sufficiently independent, documented and effective?
06 — Historical Impact
Could the issue have affected previous batches, materials, records or products?
07 — CAPA
Does the proposed CAPA address the actual systemic root cause?
08 — Effectiveness
Can objective evidence demonstrate that recurrence has been prevented?
🧫 Special Lessons for Pharmaceutical Microbiology
For pharmaceutical microbiology laboratories, Observation 1 provides
particularly useful inspection-readiness lessons.
-
Confirm that microbial identification methods are appropriately validated,
verified or otherwise qualified for their intended use.
-
Ensure the organisms relevant to the manufacturing and environmental
monitoring program are appropriately addressed by the identification system.
-
Establish scientifically justified procedures for microbial enumeration
and interpretation of high-count results.
-
Control laboratory computerized systems and permissions associated with
analytical data processing.
-
Maintain appropriate evidence demonstrating qualification and suitability
of microbiological identification systems.
💻 Data Integrity Inspection-Readiness Checklist
| Area |
Inspection-Readiness Question |
| Audit Trail |
Can the organization demonstrate that relevant audit trails are reviewed?
|
| Retention |
Are electronic records retained for the applicable required period?
|
| User Access |
Are privileges restricted according to job responsibilities?
|
| Recipe Control |
Are obsolete recipes prevented from unintended use?
|
| Change Control |
Are computerized-system changes appropriately controlled and documented?
|
| Data Review |
Can the organization demonstrate who performed reviews and what was reviewed?
|
🧼 Equipment Cleaning & Cross-Contamination Awareness
The cleaning-related observation provides an important reminder that
equipment cleaning should be considered as part of the overall product
protection strategy.
- Evaluate equipment design and cleanability.
- Define appropriate cleaning procedures.
- Establish scientifically justified acceptance criteria.
- Control product-to-product carryover risks.
- Maintain appropriate cleaning records.
- Perform verification or validation activities as applicable.
- Investigate unexpected residues or cleaning failures.
✅ FDA Inspection-Readiness Self-Assessment
Pharmaceutical organizations can use these questions as an educational
self-assessment tool:
| System |
Self-Assessment Question |
| Microbiology |
Are microbial identification methods qualified for intended use?
|
| Laboratory |
Are microbiological and analytical procedures scientifically justified?
|
| Audit Trails |
Are audit trails retained, reviewed and documented appropriately?
|
| Equipment |
Are equipment cleaning and maintenance controls effective?
|
| Computerized Systems |
Are user privileges and recipe-management controls appropriate?
|
| Data Integrity |
Can electronic records demonstrate attributable, controlled and reviewable activity?
|
| Compendial Testing |
Are applicable USP or other required specifications incorporated and implemented?
|
💡 Key Takeaway
FDA inspection readiness is not simply having SOPs.
It requires objective evidence that laboratory methods are fit for purpose,
electronic records are controlled and retained, equipment is properly cleaned,
computerized systems restrict unauthorized activities, and applicable
testing requirements are consistently implemented.
📚 Explore FDA Regulatory Resources
⚖️ Educational Disclaimer
This article is provided solely for educational, professional-development
and pharmaceutical regulatory-awareness purposes.
The information presented is based on the FDA Form 483 inspectional
observations made available for this educational discussion. The purpose
is to help pharmaceutical professionals understand potential inspection
risks and strengthen their own GMP, laboratory, microbiology, cleaning,
computerized-system and data-integrity controls.
PharmaceuticalMicrobiology.in does not intend to criticize, defame,
discredit or negatively characterize Strides Pharma Science Limited,
its management, employees, investigators or any other individual or organization.
The company name is used solely to identify the FDA inspection document
being discussed. The observations described on this page are attributed
to the FDA Form 483 and are not independent findings made by
PharmaceuticalMicrobiology.in.
An FDA Form 483 contains inspectional observations and should not by itself
be interpreted as a final FDA determination regarding a firm's compliance
status. Readers should consult the original FDA documents, applicable
regulations and official regulatory guidance for authoritative requirements.
PharmaceuticalMicrobiology.in is an independent educational website and
is not affiliated with, operated by, or endorsed by the U.S. Food and
Drug Administration (FDA).
Pharmaceuticalmicrobiology.in
Learn from FDA observations • Strengthen GMP systems • Improve inspection readiness
Comments
Post a Comment
💬 Share your thoughts or questions about this topic below.
Ask your real microbiology lab problems, deviations, or GMP doubts here.
I personally reply with practical solutions from industry experience.